Publication :: IntegralBioScience.com

Our teams, facility and working environment are geared towards making the innovation faster, efficient and successful.
As a drug discovery CRO, IBS is armed with experience, scientific tools, computer aided drug designing, expertise in chemistry, analytical instrumentation, in-vitro pharmacology and ADME.
Dedicated teams include the best and brightest talent trained at Indian/International elite universities for which achieving the scientific goals is the sole priority.

Posters & Publications

DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE.

Chakravarty et al WO2019142128.

Talazoparib efficacy is enhanced by non-cytotoxic doses of Temozolomide-Mediated DNA damage in prostate cancer cell line.

Jeffrey N. Lindquist et al AACR DNA Repair: Tumor Development and Therapeutic Response Special Conference, November 2–5, 2016, Montreal, Quebec, Canada, Poster B30.

Download PDF

Temozolomide analogs with improved brain/plasma ratios

Roopa Rai et al Bioorganic & Medicinal Chemistry Letters 26 (2016) 5103–5109.

Download PDF

Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.

Pradeep S. Jadhavar et al Bioorganic & Medicinal Chemistry Letters 26 (2016) 5222–5228.

Download PDF

Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.

Brahmam Pujala et al ACS Medicinal Chemistry Letters7 (2016), 1161−1166.

Download PDF

Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.

Amantullah Ansari et al Bioorganic & Medicinal Chemistry Letters 27 (2017) 217–222.

Download PDF

Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).

Sreekanth A. Ramachandran et al Bioorganic & Medicinal Chemistry Letters 27 (2017) 750 - 754.

Download PDF

Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors

Sreekanth A. Ramachandran et al Bioorganic & Medicinal Chemistry Letters 27 (2017), 2153 – 2160.

Download PDF

Dual Inhibition of Bruton’s Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin’s B Cell Malignancies.

Jennifer Alfaro et al J Pharmacol Exp Ther 361:312-321, May 2017.

Download PDF

Drug Discovery CRO

Posters & Publications

DUAL INHIBITORS OF ALK5 AND P38A MAP KINASE.

Talazoparib efficacy is enhanced by non-cytotoxic doses of Temozolomide-Mediated DNA damage in prostate cancer cell line.

Temozolomide analogs with improved brain/plasma ratios

Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.

Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.

Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR.

Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).

Design, synthesis and optimization of bis-amide derivatives as CSF1R inhibitors

Dual Inhibition of Bruton’s Tyrosine Kinase and Phosphoinositide-3-Kinase p110δ as a Therapeutic Approach to Treat Non-Hodgkin’s B Cell Malignancies.